Stockscreener 앱 받기
21.42
4.03%
0.83
시간 외 거래:
21.46
0.04
+0.19%
Damora Therapeutics Inc 주식(DMRA)의 최신 뉴스
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEPS Guidance Update - newsline.com
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
TD Cowen initiates Damora Therapeutics stock rating at Buy - Investing.com UK
TD Cowen initiates Damora Therapeutics stock rating at Buy By Investing.com - Investing.com India
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - AOL.com
Damora Therapeutics Inc (DMRA) SEC filings - GuruFocus
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
FCPM III Services Buys 2.44 Million Shares of Damora Therapeutics - asatunews.co.id
FCPM III Services Acquires Millions of Damora Therapeutics Shares - HarianBasis.co
Damora Therapeutics, Inc.Common Stock (Nasdaq:DMRA) Stock Quote - The Chronicle-Journal
DMRA Q1 2026 Earnings: EPS Misses Estimates by a Wide MarginSubscription Growth Report - newsline.com
Damora Therapeutics (DMRA) Receives Outperform Rating and $35 Ta - GuruFocus
DMRA Initiated by Wedbush -- Price Target Announced at $35.00 - GuruFocus
DMRA Q1 2026 Earnings: EPS Misses Estimates by Over 50%, Stock SlipsOne-Time Gain Impact - newsline.com
DMRA Technical Analysis & Stock Price Forecast - Intellectia AI
DMRA Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares LowerQuarterly Profit Report - The Legal Advocate
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations (NASDAQ:DMRA) - Seeking Alpha
Damora Therapeutics (DMRA) Gains 2.4% as Biotech Sector Finds FootingTriple Bottom - newsline.com
Damora Therapeutics (DMRA) Holds Steady Near Support: Technical Analysis of Key LevelsAnalyst Downgrade Signals - The Legal Advocate
Damora Therapeutics Holds Steady Near Key Support Amid Quiet TradingAdaptive Moving Average - The Legal Advocate
Damora Therapeutics’ Deepening Losses Raise a Quiet Question About Its Cost Strategy and Runway (DMRA) - simplywall.st
2.60%
0.94%
자본화:
|
볼륨(24시간):